Introduction Osteoporosis and fractures are common in chronic liver disease and fracture incidence increases after orthotopic liver transplantation (OLT). The value of bone turnover markers (BTMs) in the prediction of bone loss and fracture risk pre-and post-OLT remains unclear.
Over the past two decades, there has been increasing interest in the use of bone turnover markers (BTMs) in the prediction of bone loss and of fracture risk, and in the monitoring of the efficacy of treatment of osteoporosis with bone modifying agents particularly in postmenopausal women. (18) (19) (20) (21) BTMs are biochemical products of bone remodelling, which reflect the metabolic activity of bone. Alterations in bone remodelling are in turn associated with changes in bone microarchitecture and increased fracture risk. BTMs are released in the circulation where they can be measured in serum, and excreted by the kidneys, when they can be measured in urine.
In patients with chronic liver disease, there has been considerable heterogeneity of data on indices of bone remodelling particularly when set against data from the gold standard histomorphometric analysis of bone biopsy specimens obtained mostly before and within the first 6 months after OLT. Reported BTM data suggest no increase in bone turnover (15;22-24) , or increased bone turnover particularly increased bone resorption before transplantation (4;25-28) . (30) However, the position paper also underlined that the clinical value of BTMs remains somewhat limited by amongst other causes the inadequate appreciation of the sources of variability of these markers. Interpreting data on bone turnover markers represents an even greater challenge in patients with liver disease as collagen type I is produced and degraded at increased rates in patients with liver fibrosis as previously reported by Guanabens et al in 22 patients with primary biliary cirrhosis.(31) Data on BTMs before and in the short-term after OLT are conflicting (3;32-37) , and there are no long-term data on sequential changes in BTMs after OLT.
The aim of our study was to assess the value of BTMs in the prediction of bone loss and fracture risk within the first year after OLT in a well characterized population of liver transplant recipients in whom sequential BTMs, BMD data and conventional spinal radiographs were available before and during the first year after liver transplantation.
Patients and methods

Patients
Consecutive patients who underwent a first OLT at the Leiden University Medical Centre between January 1 st 2008 and January 1 st 2011 and who had available BTM measurements (either directly measured or measured from stored sera) at time of screening for OLT were eligible for inclusion the study. Excluded were patients who were treated with bisphosphonates, and those who received a second OLT or a renal transplant during the study period. The date of January 1 st 2008 for start of the study was selected because of the availability of P1NP measurements in our Clinic from this time onwards. A period of alcohol abstinence of at least six months was a prerequisite for screening for OLT in patients with alcoholic liver disease. Post-OLT immunosuppressive regimens consisted of corticosteroids for at least 6 months in all patients, combined with a calcineurin inhibitor: cyclosporine or tacrolimus in the majority, with mofetil mycophenolate (MMF) or sirolimus as additional second or third immunosuppressive agent in a few. Basiliximab was administered in the anhepatic phase and on day four after transplantation. Corticosteroid schedules included methylprednisolone at a dose of 500 mg given twice during the OLT procedure, followed by oral prednisolone at a dose of 20 mg/day for one week, 10 mg/day for 3 months, slowly tapering to complete discontinuation of corticosteroids between 3 and 6 months after OLT in all but a few patients who required maintenance doses of prednisolone of 20-40mg/day in divided doses. Treatment with calcium and vitamin D supplements at a combined fixed dose of 500 mg elemental calcium and 400 IU cholecalciferol was initiated in the majority of patients at some stage after OLT.
The study was approved by the Medical Ethics Committee of the Leiden University Medical Centre.
methods
Demographic and clinical data
Demographic and clinical data were obtained from the patients' electronic hospital records. Data on age, gender, smoking, height, weight and primary liver disease were collected. Medication including immunosuppressive agents, calcium and vitamin D supplements and bone-modifying medication such as bisphosphonates was recorded.
Data were also collected on date and cause of death.
Biochemical investigations
Laboratory data were obtained from the patients' electronic hospital records. Health Organization (WHO) criteria were used to define osteoporosis (T-score of -2,5 SD or less) and osteopenia (T-score between -1 SD and -2.5 SD). 41 patients were male (80%) and median age was 59 years (range 23-66 years) (Table 1) . Most common primary liver disease was alcoholic liver disease (41%) followed by viral liver disease (26%) and cholestatic liver disease (4%). Only one patient died of an unknown cause 211 days after OLT. At time of screening, 4 patients (8%) were using calcium and vitamin D supplements and 1 patient was receiving treatment with corticosteroids.
Biochemical parameters
At time of screening, mean creatinine level was 88 ± 37 µmol/L. Mean 25(OH)D level was 36 ± 27 nmol/L, with 82% of patients having levels of < 50 nmol/L and 43% of patients of < 25 nmol/L. Mean bilirubin level was 96 ± 212 mmol/L and mean MELD score was 13 ± 6.
Prevalent BMD
BMD was available at screening in 50 of the 51 patients. Lumbar spine (LS) data were not interpretable in two patients because of residual oral contrast material from abdominal CT-scans, required as part of the screening protocol for OLT, but chronologically performed by error before DXA. Mean LS BMD was 1.00 ± 0.16 g/cm 2 and mean femoral neck (FN) was 0.80 ± 0.14 g/cm 2 at the FN. The prevalence of osteoporosis and osteopenia was respectively 16 and 33 % at the LS and 4 and 44% at the FN. 
Prevalent vertebral fractures
Conventional spinal radiographs were available in all patients. Vertebral fractures were prevalent at time of screening in 34 patients (67%), mostly grade 1 fractures.
Bone turnover markers
Mean P1NP level was 82 ± 47 ng/mL (normal < 59 ng/mL). Mean osteocalcin levels was 9 ± 4 ug/L (mean Z-score -0.9 ± 1.6), mean BALP was 22 ± 9 U/L (mean Z-score 0.82 OLT = orthotopic liver transplantation; BMI = body mass index; PSC = primary sclerosing cholangitis; PBC = primary biliary cirrhosis; MMF = mycofenolate mofetil. * including polycystic liver disease, cryptogenic cirrhosis, non-alcoholic steatosis hepatis, Caroli syndrome ±1.7) and mean CTX level was 397 ± 326 pg/mL (mean Z-score 2.16 ± 3.5). There was a significant relationship between P1NP and CTX levels (p < 0.005), which was no longer significant after correcting for creatinine levels (p = 0.060). (Figure 2 ) There was no relationship between CTX and osteocalcin or BALP Higher creatinine levels were associated with higher levels of P1NP (p<0.005), osteocalcin (p<0.005) and CTX (p < 0.005). There was no association between creatinine levels and BALP (p=0.984).
At time of screening, higher MELD scores were associated with higher P1NP levels (p < 0.005) and higher CTX levels (p <0.005). There was no association between MELD scores and BALP or osteocalcin levels (p = 0.070 and p = 0.260 respectively). There was no significant association between bilirubin levels or INR and any of the BTM's before transplantation. Higher albumin levels were associated with lower CTX levels (p = 0.015).
Despite the low mean vitamin D levels at screening for OLT, there was no association between any BTM measured and 25(OH)D levels at this time point.
At screening, higher CTX levels but none of the other BTMs were predictive for lower BMD at the LS (p = 0.009) but not at the FN. None of the markers were predictive for prevalent vertebral fractures.
b. follow-up data in the first year after olt
Clinical parameters
Median time between screening and OLT was 9 months. After OLT, all patients were treated with prednisone, which was combined with tacrolimus in the majority of patients (78%) or tacrolimus and MMF (12%). Cyclosporine combined with MMF was added to 
Changes in BMD
There was no significant change in LS BMD at 6 or 12 months after OLT compared to baseline. Mean BMD at the LS was 1.01 ± 0.15 g/cm 2 at twelve months after OLT compared to 1.00 ± 0.16 g/cm 2 at baseline ( p = 0.236). There was however, a significant decrease in FN BMD after OLT from 0.79 ± 0.13 g/cm 2 at time of screening to 0.75 ± 0.12 g/cm 2 at six months after OLT (p < 0.005) remaining stable thereafter with a mean BMD of 0.77±0.14 g/cm 2 at twelve months after OLT ( p = 0.438 compared to values six months after OLT).
Incident fractures during the first year after OLT
Conventional spinal radiographs were available and evaluable in 49 of the 51 patients included in the study: in 45 at 6 months after OLT and in 37 patients at 12 months after OLT.
Within the first year after OLT, new fractures were documented in 21 of the 49 patients (43%).
Bone turnover markers
Changes in BTMs were analysed in all patients included in the study. A separate analysis was also conducted in patients without incident vertebral fractures (n = 28) to avoid the possible effect of a recent fracture on the interpretation of BTMs. In the whole group, P1NP decreased after OLT from 82 ± 47 ng/mL at screening to 68 ± 38 ng/mL at three months and 77 ± 52 ng/mL at six months, both non-significantly, only reaching significance at twelve months after OLT with a level of 65 ± 50 ng/mL (p = 0.005) ( Figure   3 ). In patients without incident vertebral fractures during the first year after OLT, P1NP also decreased significantly (p = 0.003 at 12 months after OLT) whereas it did not in 
c. Predictive value of btms at screening for olt for bone loss and fracture incidence up to a year after transplantation
Higher CTX levels were associated with a decrease in LS (p = 0.008) as well as FN BMD (p=0.039). P1NP, BALP and osteocalcin levels measured at screening were not predictive 
discussion
Our data from this study demonstrate the limited value of the widely used bone turnover markers in the prediction of bone loss and of fracture risk before and after orthotopic liver transplantation. Although P1NP levels were increased and osteocalcin levels were decreased at screening before OLT, these markers as well as baseline bone alkaline phosphatase were neither predictive for prevalent BMD or prevalent vertebral fractures before transplantation, nor were they predictive for bone loss or increased fracture risk after transplantation. Only increased CTX levels at time of screening for OLT were predictive for bone loss and increased fracture risk after OLT. An increase in BALP at 6 months after OLT was also predictive for increased fracture risk a year after OLT.
Bone turnover markers are biochemical products of bone remodelling, which reflect the metabolic activity of bone, and can be easily measured in serum or urine using semi- be easily and reliably measured. However, although most circulating P1NP is mainly derived from pro-collagen secreted by osteoblasts during the process of bone formation (39) and collagen type I constitutes more than 90% of the organic bone matrix. P1NP is not strictly speaking a bone-specific marker as it is also released in the circulation by fibroblasts in soft connective tissue, including hepatic connective tissue. P1NP is thus as much a serum marker of connective tissue metabolism as it is of bone metabolism. P1NP
is cleared from the circulation by both renal and liver extraction so that impairment of either or both clearing mechanisms by liver and/or renal impairment may influence its serum levels. On the other hand, P1NP measurements are stable with minimal diurnal variation and no effect of food on circulating levels.
In our study, we could find no association between the high baseline P1NP values and either prevalent BMD or prevalent fractures before transplantation, or bone loss or increased fracture risk post-transplantation. In chronic liver disease, the marked increase in connective tissue synthesis and degradation of hepatic collagen type I (40;41), which does not reflect bone remodelling but rather liver fibrogenicity, has been previously demonstrated in animal models of liver fibrosis (42) , in patients with progressive fibrosis of the liver due to primary biliary cirrhosis and in patients with alcoholic liver cirrhosis (31;43) . In our study, we observed a significant decrease in P1NP levels after OLT, parallel with increases in osteocalcin levels, both closely related to improvement in hepatobiliary function as shown by significant post-OLT decreases in bilirubin levels( Figure 4) . Intriguingly, we could not demonstrate a significant relationship between bilirubin levels and P1NP either at baseline or within the first year after transplantation, although both markers showed parallel decreases with time. A reason for this is likely to be that although bilirubin is a useful marker of liver function, it may not be a sufficient surrogate marker for all aspects of liver function.
Osteocalcin is a non-collagenous protein of the bone matrix, exclusively synthesized by the osteoblast during the process of bone formation, which should have potentially been a more useful marker of bone turnover in patients with liver disease as it is a noncollagen-derived marker and it is mainly cleared by the kidney so that it would not be affected by abnormal hepatic collagen production. (44;45) Our data confirm this premise as we could show no association between osteocalcin and MELD scores, bilirubin, INR or albumin. However, osteocalcin was disappointly also not predictive for either bone loss or increased fracture risk after OLT. A possible explanation for this may be that osteocalcin synthesis is vitamin K dependent (45) , and that levels may decrease due to decreased synthesis of vitamin K in patients with end-stage liver failure. Osteocalcin is also rapidly degraded in serum to heterogeneous fragments and its circulating levels are influenced by circadian rhythms and by renal function, which is often disturbed in patients with end-stage liver disease before and after OLT. has been shown to be one of the most sensitive markers of bone resorption with a more consistent association with fracture risk than bone formation markers (46) . However, CTX is a marker of bone resorption based on collagen degradation, which has also been found to be increased in patients with primary biliary cirrhosis just as P1NP is.(31) It is thus likely that in liver failure, measured levels of CTX would not exclusively reflect degradation of bone collagen, but also that of increased hepatic collagen synthesis and degradation. Higher MELD scores, reflecting severity of liver disease, were indeed associated with higher CTX levels which supports a relationship between hepatobiliary function and CTX.
Interestingly, however, high pre-transplantation levels of CTX were predictive not only of post-transplantation bone loss, but also of increased fracture risk. The better predictive value of a bone resorption marker over that of a bone formation marker for fracture risk is that bone formation lags behind bone resorption, needing some 3 months or more to fill the newly formed resorption cavities, in the process of which, the unfilled resorbed areas would significantly weaken the microarchitecture of bone resulting in a decrease in bone quality and a consequent increase in bone fragility, independently of the actual amount of bone lost. Our data are in keeping with this premise, showing an increased fracture risk associated with persistently increased levels of the bone resorption marker CTX and with increasing bone turnover as suggested by increasing bone alkaline phosphatase levels, despite the absence of significant bone loss at the lumbar spine as suggested by stable BMD values at this site in the first year after OLT.
Our study has strengths as well as limitations. A main strength of the study is that the cohort studied is representative of a liver transplantation cohort. A predefined protocol was applied with BMD measurements and conventional radiographs of the spine being routinely undertaken and thus available at screening and at regular intervals thereafter in the majority of patients. A further strength of our study is the long established practice of storage of sera in a Biobank in the Liver Transplantation Program, as a result of which stored serum samples could be analysed in case of missing data and further used for the measurement of P1NP, osteocalcin, BALP and CTX.
Our study has also a number of limitations. One of the limitations is the lack of a well-defined marker of liver function except for the validated laboratory MELD score.
This score includes in addition to bilirubin and INR, creatinine and albumin as surrogate markers for the poorly prognostic hepatorenal syndrome. Whereas MELD scores are commonly used to evaluate severity of liver disease and thus of prognosis at the time of screening before OLT, these scores are not actually validated for the evaluation of liver function after OLT. A further limitation of our study is the relatively small number of patients included in the study, which may have precluded the detection of significant differences due to lack of power.
The fact that serum measured for CTX was not collected as recommended in the fasting state due to the retrospective nature of our study may also be perceived as a limitation in the interpretation of our results due to the known circadian rhythm of the marker and the influence of food intake on its circulating levels. However, it has been shown that non-fasting levels of CTX are about 20% lower than fasting ones, so that measured non-fasting levels would represent if anything an underestimate of the actual levels. It has also been previously shown that the afternoon level of CTX was more closely related to fracture risk than the morning sample. (47) Although biochemical markers of bone turnover are widely available for use in the Clinic, their role in the prediction of bone loss and of fracture risk remains inconclusive and their value in the management of post-transplantation bone disease remains highly debatable. This is indeed the case in chronic liver disease, before and after liver transplantation, because of the many pitfalls encountered in the interpretation of these markers in the presence of disturbed connective tissue metabolism as well as the confounding effect of corticosteroids and calcineurin inhibitors used for immunosuppression.
In conclusion, our data highlight the pitfalls in the interpretation of BTMs in chronic liver disease before and after liver transplantation. Based on our findings, we would recommend that caution should be advocated with the use of BTMs in the clinic in patients with chronic liver disease before and after liver transplantation until further evidence is obtained for the value of available or newer BTMs for therapeutic decision making in the management of skeletal complications in these patients. 
